A Phase 2 interventional study of levocetirizine dihydrochloride in Cough, sponsored by UCB Pharma. Completed. Open to participants aged 2 Months to 24 Months. Per ClinicalTrials.gov, last updated 2013-12-12.
Sponsored by UCB Pharma · Phase 2, Interventional, and Treatment
Efficacy and Safety of Levocetirizine for Treatment of Recurrent Cough Associated With Other Allergic Symptoms in Children
346 studies on the registry are indexed under Cough; 71 are open to participants now.
This study's enrollment of 15 is below the median of 70 across 263 interventional studies indexed under Cough.
Browse Cough studies →UCB Pharma is the lead sponsor of 238 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The efficacy based on daily record cards recordings
Time frame: 90 days
Safety and pharmacokinetics at 90 days; skin reactivity
No study locations are listed for this record.
This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
UCB Pharma